JP2024500115A5 - - Google Patents

Info

Publication number
JP2024500115A5
JP2024500115A5 JP2023536496A JP2023536496A JP2024500115A5 JP 2024500115 A5 JP2024500115 A5 JP 2024500115A5 JP 2023536496 A JP2023536496 A JP 2023536496A JP 2023536496 A JP2023536496 A JP 2023536496A JP 2024500115 A5 JP2024500115 A5 JP 2024500115A5
Authority
JP
Japan
Prior art keywords
antibody
vector
antibody fragment
gene encoding
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500115A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/086645 external-priority patent/WO2022129609A2/en
Publication of JP2024500115A publication Critical patent/JP2024500115A/ja
Publication of JP2024500115A5 publication Critical patent/JP2024500115A5/ja
Pending legal-status Critical Current

Links

JP2023536496A 2020-12-18 2021-12-17 抗体デリバリー Pending JP2024500115A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20215823.4 2020-12-18
EP20215823 2020-12-18
PCT/EP2021/086645 WO2022129609A2 (en) 2020-12-18 2021-12-17 Antibody delivery

Publications (2)

Publication Number Publication Date
JP2024500115A JP2024500115A (ja) 2024-01-04
JP2024500115A5 true JP2024500115A5 (cg-RX-API-DMAC7.html) 2024-12-24

Family

ID=74183005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536496A Pending JP2024500115A (ja) 2020-12-18 2021-12-17 抗体デリバリー

Country Status (12)

Country Link
US (1) US20240100187A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263573A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024500115A (cg-RX-API-DMAC7.html)
KR (1) KR20230121096A (cg-RX-API-DMAC7.html)
CN (1) CN116917491A (cg-RX-API-DMAC7.html)
AR (1) AR124410A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021399147A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200807A1 (cg-RX-API-DMAC7.html)
IL (1) IL303758A (cg-RX-API-DMAC7.html)
MX (1) MX2023006973A (cg-RX-API-DMAC7.html)
TW (1) TW202242118A (cg-RX-API-DMAC7.html)
WO (1) WO2022129609A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184494A1 (en) * 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
US9790488B2 (en) * 2013-08-02 2017-10-17 Agency For Science, Technology And Research Mutated internal ribosomal entry site (IRES) for controlled gene expression
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JP2019515027A (ja) * 2016-04-15 2019-06-06 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11512327B2 (en) * 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
SG11202111249YA (en) * 2019-04-11 2021-11-29 California Inst Of Techn Virus compositions with enhanced specificity in the brain

Similar Documents

Publication Publication Date Title
JP2023145597A (ja) Rnaを編集するための組成物および方法
JP4888876B2 (ja) アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
US10787681B2 (en) Humanized viral vectors and methods of use thereof
JP2023523401A5 (cg-RX-API-DMAC7.html)
JP2023504661A5 (cg-RX-API-DMAC7.html)
JP2019515027A (ja) 翻訳後修飾された完全ヒト抗VEGF Fabを用いる眼疾患の治療
US20230242602A1 (en) Zinc finger protein transcription factors for repressing tau expression
JP2026031563A (ja) 神経系における抗原結合タンパク質の発現
WO2021067864A1 (en) Zinc finger protein transcription factors for treatment of prion disease
JP2024500115A (ja) 抗体デリバリー
SE2350348A1 (en) Microglial endocytic receptors for use in the treatment of neurodegenerative disease
RU2831086C2 (ru) Экспрессия антигенсвязывающих белков в нервной системе
WO2025076091A1 (en) Cd20 antibody aav vectors and methods of use thereof
WO2026107405A2 (en) Compositions and methods for enhanced cns delivery through a novel protein interaction
HK40103100A (en) Antibody delivery
JP2024542015A5 (cg-RX-API-DMAC7.html)
WO2024102672A2 (en) Treatment of neurological disorder using nhr
TW202547548A (zh) 使用血腦屏障穿透性蛋白殼之tau抑制子遞送
Su et al. Application to Gene Therapy and Vaccination